Physician profile
John Condit
NPI 1811909179
$3,059.60
in general payments reported to CMS, 2019-2025
18 companies · $439 in 2025
The $439 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $256 · 2021: $347 · 2022: $234 · 2023: $740 · 2024: $321 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $415.69 | 2021-2023 | Mycarelink, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| Pfizer INC. | $358.43 | 2019-2025 | |
| Abbott Laboratories | $332.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $271.84 | 2019-2024 | Camzyos |
| Medtronic Vascular, INC. | $271.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $250.97 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.41 | 2019-2025 | Jardiance |
| Amgen INC. | $179.39 | 2020-2025 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $167.07 | 2019-2024 | Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $148.85 | 2023-2025 | |
| Edwards Lifesciences Corporation | $139.49 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $80.98 | 2019-2022 | |
| Irhythm Technologies, INC. | $74.42 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Boston Scientific Corporation | $53.15 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $43.74 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $37.87 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $33.29 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $21.54 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Condit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.